PortalPublikationenPredictive immune markers in advanced melanoma patients trea...

Predictive immune markers in advanced melanoma patients treated with ipilimumab

Standard

Predictive immune markers in advanced melanoma patients treated with ipilimumab. / Umansky, Viktor; Utikal, Jochen; Gebhardt, Christoffer.

in: ONCOIMMUNOLOGY, Jahrgang 5, Nr. 6, 06.2016, S. e1158901.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Umansky, V, Utikal, J & Gebhardt, C 2016, 'Predictive immune markers in advanced melanoma patients treated with ipilimumab', ONCOIMMUNOLOGY, Jg. 5, Nr. 6, S. e1158901. https://doi.org/10.1080/2162402X.2016.1158901

APA

Umansky, V., Utikal, J., & Gebhardt, C. (2016). Predictive immune markers in advanced melanoma patients treated with ipilimumab. ONCOIMMUNOLOGY, 5(6), e1158901. https://doi.org/10.1080/2162402X.2016.1158901

Vancouver

Umansky V, Utikal J, Gebhardt C. Predictive immune markers in advanced melanoma patients treated with ipilimumab. ONCOIMMUNOLOGY. 2016 Jun;5(6):e1158901. https://doi.org/10.1080/2162402X.2016.1158901

Bibtex

@article{7a70cb725c2e415cbcded5aa53e67a08,
title = "Predictive immune markers in advanced melanoma patients treated with ipilimumab",
abstract = "Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.",
keywords = "Journal Article",
author = "Viktor Umansky and Jochen Utikal and Christoffer Gebhardt",
year = "2016",
month = jun,
doi = "10.1080/2162402X.2016.1158901",
language = "English",
volume = "5",
pages = "e1158901",
journal = "ONCOIMMUNOLOGY",
issn = "2162-402X",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Predictive immune markers in advanced melanoma patients treated with ipilimumab

AU - Umansky, Viktor

AU - Utikal, Jochen

AU - Gebhardt, Christoffer

PY - 2016/6

Y1 - 2016/6

N2 - Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.

AB - Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.

KW - Journal Article

U2 - 10.1080/2162402X.2016.1158901

DO - 10.1080/2162402X.2016.1158901

M3 - SCORING: Journal article

C2 - 27471626

VL - 5

SP - e1158901

JO - ONCOIMMUNOLOGY

JF - ONCOIMMUNOLOGY

SN - 2162-402X

IS - 6

ER -